Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

Author(s):: Hulshof, E.C.; With, M. de; Creemers, G.J.; Guchelaar, H.J. (0000-0002-7085-1383); Mathijssen, R.H.; Gelderblom, H.; Deenen, M.J.

Published: 2022
Publication type: Article / Letter to editor

Date issued: 2022-07-03
Language: English
Publisher: ELSEVIER SCI LTD
Is part of
hdl: 1887/3593869
doi: 10.1016/j.ejca.2022.05.045